Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BML ( (JP:4694) ) is now available.
BML, Inc. has corrected previously disclosed figures in its consolidated earnings report for the third quarter of fiscal 2025, revising total assets upward while leaving net assets unchanged. The company reported that total assets as of December 31, 2025 were ¥182,201 million instead of ¥176,860 million, reducing the equity ratio from 71.1% to 69.0%.
The revised data also adjust the comparison with the prior fiscal year-end, now showing a ¥671 million decrease in total assets from March 31, 2025 instead of ¥646 million, while the decline in net assets remains ¥3,642 million. These corrections slightly worsen BML’s reported capital structure metrics, which may refine investors’ view of its balance sheet strength but do not alter the underlying net asset trend disclosed in the original report.
The most recent analyst rating on (JP:4694) stock is a Hold with a Yen4260.00 price target. To see the full list of analyst forecasts on BML stock, see the JP:4694 Stock Forecast page.
More about BML
BML, Inc. is a Japan-based company listed on the Tokyo Stock Exchange Prime market under securities code 4694. The company operates in the medical testing and laboratory services industry, providing clinical testing and related diagnostic services primarily to healthcare institutions in Japan.
YTD Price Performance: 3.63%
Average Trading Volume: 59,994
Technical Sentiment Signal: Buy
Current Market Cap: Yen149.6B
Find detailed analytics on 4694 stock on TipRanks’ Stock Analysis page.